https://www.selleckchem.com/pr....oducts/bso-l-buthion
BACKGROUND Regorafenib is an oral small-molecule multikinase inhibitor approved in third or later line of treatment for patients with metastatic colorectal cancer (mCRC). Regorafenib has shown significant benefits in overall survival and progression free survival in two phase III trials compared to placebo in patients with mCRC who had progressed on previous therapy. AIM To identify an immune profile that might specifically correlate with the outcome in patients treated with regorafenib. METHODS Blood samples we
Like
Comment
Share
